S&P 500   4,356.45 (-1.22%)
DOW   34,297.73 (-0.19%)
QQQ   345.11 (-2.32%)
AAPL   159.78 (-1.14%)
MSFT   288.49 (-2.66%)
FB   300.15 (-2.77%)
GOOGL   2,538.70 (-2.96%)
AMZN   2,799.72 (-3.15%)
TSLA   918.40 (-1.25%)
NVDA   223.24 (-4.48%)
BABA   119.14 (-1.02%)
NIO   23.79 (-4.34%)
AMD   111.13 (-4.63%)
CGC   7.36 (-0.54%)
MU   80.72 (-2.69%)
GE   91.11 (-5.98%)
T   26.48 (+0.53%)
F   19.98 (-2.01%)
DIS   136.51 (-0.69%)
AMC   16.02 (-3.73%)
PFE   52.54 (+1.94%)
ACB   4.21 (-2.55%)
BA   204.10 (-0.05%)
S&P 500   4,356.45 (-1.22%)
DOW   34,297.73 (-0.19%)
QQQ   345.11 (-2.32%)
AAPL   159.78 (-1.14%)
MSFT   288.49 (-2.66%)
FB   300.15 (-2.77%)
GOOGL   2,538.70 (-2.96%)
AMZN   2,799.72 (-3.15%)
TSLA   918.40 (-1.25%)
NVDA   223.24 (-4.48%)
BABA   119.14 (-1.02%)
NIO   23.79 (-4.34%)
AMD   111.13 (-4.63%)
CGC   7.36 (-0.54%)
MU   80.72 (-2.69%)
GE   91.11 (-5.98%)
T   26.48 (+0.53%)
F   19.98 (-2.01%)
DIS   136.51 (-0.69%)
AMC   16.02 (-3.73%)
PFE   52.54 (+1.94%)
ACB   4.21 (-2.55%)
BA   204.10 (-0.05%)
S&P 500   4,356.45 (-1.22%)
DOW   34,297.73 (-0.19%)
QQQ   345.11 (-2.32%)
AAPL   159.78 (-1.14%)
MSFT   288.49 (-2.66%)
FB   300.15 (-2.77%)
GOOGL   2,538.70 (-2.96%)
AMZN   2,799.72 (-3.15%)
TSLA   918.40 (-1.25%)
NVDA   223.24 (-4.48%)
BABA   119.14 (-1.02%)
NIO   23.79 (-4.34%)
AMD   111.13 (-4.63%)
CGC   7.36 (-0.54%)
MU   80.72 (-2.69%)
GE   91.11 (-5.98%)
T   26.48 (+0.53%)
F   19.98 (-2.01%)
DIS   136.51 (-0.69%)
AMC   16.02 (-3.73%)
PFE   52.54 (+1.94%)
ACB   4.21 (-2.55%)
BA   204.10 (-0.05%)
S&P 500   4,356.45 (-1.22%)
DOW   34,297.73 (-0.19%)
QQQ   345.11 (-2.32%)
AAPL   159.78 (-1.14%)
MSFT   288.49 (-2.66%)
FB   300.15 (-2.77%)
GOOGL   2,538.70 (-2.96%)
AMZN   2,799.72 (-3.15%)
TSLA   918.40 (-1.25%)
NVDA   223.24 (-4.48%)
BABA   119.14 (-1.02%)
NIO   23.79 (-4.34%)
AMD   111.13 (-4.63%)
CGC   7.36 (-0.54%)
MU   80.72 (-2.69%)
GE   91.11 (-5.98%)
T   26.48 (+0.53%)
F   19.98 (-2.01%)
DIS   136.51 (-0.69%)
AMC   16.02 (-3.73%)
PFE   52.54 (+1.94%)
ACB   4.21 (-2.55%)
BA   204.10 (-0.05%)
NASDAQ:ENTA

Enanta Pharmaceuticals News Headlines

$58.59
+0.18 (+0.31%)
(As of 01/25/2022 12:00 AM ET)
Add
Compare
Today's Range
$56.63
$59.98
50-Day Range
$56.49
$92.58
52-Week Range
$40.37
$102.00
Volume
199,792 shs
Average Volume
216,850 shs
Market Capitalization
$1.19 billion
P/E Ratio
N/A
Dividend Yield
N/A
Beta
0.53
Get Enanta Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for ENTA and its competitors with MarketBeat's FREE daily newsletter.

Media Mentions By Week

Enanta Pharmaceuticals Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

ENTA
News Sentiment

0.09

0.35

Average
Medical
News Sentiment

Media Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

ENTA Articles
This Week

4

1

ENTA Articles
Average Week



Enanta Pharmaceuticals (NASDAQ:ENTA) News Headlines Today

SourceHeadline
nasdaq.com logoENTA Makes Notable Cross Below Critical Moving Average
nasdaq.com - January 14 at 3:26 PM
MarketBeat logoNathalie Adda Sells 12,536 Shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Stock
americanbankingnews.com - January 13 at 9:32 PM
seekingalpha.com logoEnanta under pressure after SVB Leerink slashed price target
seekingalpha.com - January 13 at 4:09 PM
markets.businessinsider.com logoWhat 10 Analyst Ratings Have To Say About Enanta Pharmaceuticals
markets.businessinsider.com - January 13 at 4:09 PM
MarketBeat logoEnanta Pharmaceuticals (NASDAQ:ENTA) Price Target Cut to $80.00
americanbankingnews.com - January 13 at 9:18 AM
MarketBeat logoEnanta Pharmaceuticals (NASDAQ:ENTA) Shares Down 3.9%
americanbankingnews.com - January 11 at 1:48 PM
seekingalpha.com logoEnanta Pharmaceuticals rises on pipeline updates for 2022
seekingalpha.com - January 6 at 7:27 PM
finance.yahoo.com logoEnanta Pharmaceuticals to Provide Updates on its Research and Development Programs and Outlook for 2022 at the 40th Annual J.P. Morgan Healthcare Conference
finance.yahoo.com - January 6 at 9:26 AM
finance.yahoo.com logoEnanta Pharmaceuticals to Present at the 40th Annual J.P. Morgan Healthcare Conference
finance.yahoo.com - January 4 at 9:11 AM
seekingalpha.com logoEnanta Pharmaceuticals, Inc. 2021 Q4 - Results - Earnings Call Presentation
seekingalpha.com - December 3 at 11:44 AM
nasdaq.com logoEnanta Pharmaceuticals Reaches Analyst Target Price
nasdaq.com - November 29 at 1:10 PM
finance.yahoo.com logoHealth Check: How Prudently Does Enanta Pharmaceuticals (NASDAQ:ENTA) Use Debt?
finance.yahoo.com - November 25 at 8:23 AM
finance.yahoo.com logoEnanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year Ended September 30, 2021 with Webcast and Conference Call Today at 4:30 p.m. ET
finance.yahoo.com - November 22 at 8:13 PM
finance.yahoo.com logoEnanta Pharmaceuticals (ENTA) Reports Q4 Loss, Lags Revenue Estimates
finance.yahoo.com - November 22 at 8:13 PM
benzinga.com logoEnanta Pharmaceuticals's Earnings: A Preview
benzinga.com - November 19 at 5:54 PM
finance.yahoo.com logoIs a Surprise Coming for Enanta Pharmaceuticals (ENTA) This Earnings Season?
finance.yahoo.com - November 19 at 12:53 PM
finance.yahoo.com logoEnanta Pharmaceuticals Announces Update to its Hepatitis B Virus (HBV) Program
finance.yahoo.com - November 18 at 8:38 PM
finance.yahoo.com logoEnanta Pharmaceuticals to Host Conference Call on November 22 at 4:30 p.m. ET to Discuss its Financial Results for its Fiscal Fourth Quarter and Year Ended September 30, 2021
finance.yahoo.com - November 15 at 6:55 PM
markets.businessinsider.com logoEnanta Pharma Reports Positive Data From Phase 1b Studies Of EDP-514 - Quick Facts
markets.businessinsider.com - November 12 at 9:24 AM
finance.yahoo.com logoEnanta Pharmaceuticals Reports Positive Final Data from its Phase 1b Studies of EDP-514, a Novel Hepatitis B Virus Core Inhibitor
finance.yahoo.com - November 12 at 9:24 AM
finance.yahoo.com logoNotable Enanta Pharmaceuticals Insider Trades $1.3M In Company Stock
finance.yahoo.com - November 3 at 6:02 PM
finance.yahoo.com logoEnanta Plans To Start Human Trials For Its COVID-19 Candidate In 2022
finance.yahoo.com - October 19 at 5:50 PM
finance.yahoo.com logoEnanta Pharmaceuticals Presents New Data for EDP-235, its Lead Oral Protease Inhibitor Designed for the Treatment of COVID-19, at the ISIRV–WHO Virtual Conference 2021
finance.yahoo.com - October 19 at 7:48 AM
benzinga.com logoSenior VP And Chief Medical Officer Of Enanta Pharmaceuticals Trades $2.0M In Company Stock
benzinga.com - October 14 at 1:30 PM
finance.yahoo.com logoEnanta Pharmaceuticals (ENTA) Moves 10.6% Higher: Will This Strength Last?
finance.yahoo.com - October 8 at 1:43 PM
markets.businessinsider.com logoWhere Enanta Pharmaceuticals Stands With Analysts
markets.businessinsider.com - October 7 at 2:30 PM
nasdaq.com logoEnanta Pharmaceuticals Inc Shares Near 52-Week High - Market Mover
nasdaq.com - October 6 at 2:06 PM
finance.yahoo.com logoNew Preclinical Data for EDP-235, Enanta’s Oral Protease Inhibitor Specifically Designed for the Treatment of COVID-19, to be Presented at ISRIV-WHO Virtual 2021 Conference: COVID-19, Influenza and RSV: Surveillance-Informed Prevention and Treatment
finance.yahoo.com - October 6 at 2:06 PM
finance.yahoo.com logoEnanta Pharmaceuticals to Present at the H.C. Wainwright 2nd Annual Hepatitis B Virus Virtual Conference
finance.yahoo.com - October 5 at 10:30 AM
finance.yahoo.com logoEnanta To Discontinue Internal Development Of NASH Candidates
finance.yahoo.com - October 5 at 12:28 AM
finance.yahoo.com logoEnanta Pharmaceuticals Provides Update on NASH FXR Agonist Programs
finance.yahoo.com - October 4 at 12:00 PM
finance.yahoo.com logoEnanta Pharmaceuticals Announces Data Presentations at AASLD’s The Liver Meeting® 2021
finance.yahoo.com - October 1 at 9:43 AM
finance.yahoo.com logoEnanta Pharmaceuticals to Participate in Investor Conferences in September
finance.yahoo.com - September 7 at 11:25 AM
nasdaq.com logoEnanta Pharmaceuticals Inc Shares Close in on 52-Week High - Market Mover
nasdaq.com - August 28 at 6:06 PM
finance.yahoo.com logoEnanta Pharmaceuticals Elects Yujiro S. Hata to its Board of Directors
finance.yahoo.com - August 23 at 8:25 AM
finance.yahoo.com logoEnanta Pharmaceuticals Doses First Subject in a Phase 1 Clinical Study of EDP-721, Its Oral Hepatitis B Virus RNA Destabilizer
finance.yahoo.com - August 16 at 7:28 AM
finance.yahoo.com logoThose who invested in Enanta Pharmaceuticals (NASDAQ:ENTA) five years ago are up 97%
finance.yahoo.com - August 13 at 4:43 PM
finance.yahoo.com logoEnanta Pharmaceuticals, inc (ENTA) Q3 2021 Earnings Call Transcript
finance.yahoo.com - August 6 at 10:05 AM
finance.yahoo.com logoEnanta Pharmaceuticals Reports Financial Results for Its Fiscal Third Quarter Ended June 30, 2021 with Webcast and Conference Call Today at 4:30 p.m. ET
finance.yahoo.com - August 5 at 6:16 PM
finance.yahoo.com logoEnanta Pharmaceuticals Announces Nomination of Clinical Candidate EDP-235, its Lead Oral Protease Inhibitor Specifically Designed for the Treatment of COVID-19
finance.yahoo.com - August 5 at 8:16 AM
finance.yahoo.com logoEnanta Pharmaceuticals to Host Conference Call on August 5 at 4:30 p.m. ET to Discuss its Financial Results for its Fiscal Third Quarter Ended June 30, 2021
finance.yahoo.com - July 29 at 10:19 AM
finance.yahoo.com logoEarnings Preview: Enanta Pharmaceuticals (ENTA) Q3 Earnings Expected to Decline
finance.yahoo.com - July 27 at 7:40 PM
nasdaq.com logoEnanta Pharmaceuticals, Inc. Common Stock (ENTA)
nasdaq.com - July 17 at 6:50 PM
marketwatch.com logoEnanta Pharmaceuticals Announces the Planned Retirement of Chief Medical OfficerNathalie Adda, M.D.
marketwatch.com - July 16 at 10:57 PM
finance.yahoo.com logoEnanta Pharmaceuticals Announces the Planned Retirement of Chief Medical Officer Nathalie Adda, M.D.
finance.yahoo.com - July 14 at 10:13 PM
uk.finance.yahoo.com logoENTA Jan 2022 55.000 call
uk.finance.yahoo.com - June 30 at 11:33 PM
msn.com logoBRIEF-Enanta Pharmaceuticals Presents New Data For EDP-721
msn.com - June 23 at 5:38 AM
businesswire.com logoEnanta Pharmaceuticals Presents New Data for EDP-721, an Oral Hepatitis B Virus RNA Destabilizer, at the European Association for the Study of the Liver (EASL) International ...
businesswire.com - June 23 at 5:38 AM
finance.yahoo.com logoEnanta Pharmaceuticals Presents New Data for EDP-721, an Oral Hepatitis B Virus RNA Destabilizer, at the European Association for the Study of the Liver (EASL) International Liver Congress™
finance.yahoo.com - June 23 at 5:38 AM
msn.com logoBRIEF-Enanta Pharma Reports Positive Data From Phase 1B Study Of EDP-514, A Hepatitis B Virus Core Inhibitor
msn.com - June 22 at 5:33 PM
Get Enanta Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for ENTA and its competitors with MarketBeat's FREE daily newsletter.

This page was last updated on 1/25/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.